Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Double Medical Technology Inc. (002901.SZ)
Xiamen, CN
Double Medical Technology Inc. is a medical enterprise offering a diverse array of services, advanced technologies, and specialized devices. Primarily serving the Chinese market, its core competencies lie in orthopedics, wound management, neurosurgery, and general surgical solutions. The company also boasts an international footprint, distributing its products to approximately 50 countries and regions worldwide, including the European Union, Russia, South America, Australia, Southeast Asia, the Middle East, and South Africa. Founded in 2004 under its previous name, Xiamen Da Bo Ying Jing Medical Equipment Company Limited, Double Medical Technology Inc. is headquartered in Xiamen, People's Republic of China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.88% | -4.78% | -5.86% | -14.79% | -17.71% | -13.87% | +6.14% | +27.54% | -36.04% | +145.05% | +145.05% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Devices: +11.2%+21.8% ★ Q1'26: +16.6% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%+70.9% ★ Q1'26: +44.0% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%+21.6% ★ Q1'26: +4.9% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%+28.3% ★ Q1'26: +26.2% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%+28.3% ★ Q1'26: +24.5% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%-2.0% ★ Q1'26: -0.9% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×0.34× ★ Q1'26: 0.54× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
594.01M
est: 543.00M (+9.4%)
|
772.47M
est: 757.00M (+2.0%)
|
1.26B
est: 1.27B (-1.0%)
|
1.59B
est: 1.65B (-3.7%)
|
1.99B
est: 1.93B (+3.4%)
|
1.43B
est: 2.32B (-38.2%)
|
1.53B
est: 1.52B (+1.2%)
|
2.14B
est: 2.02B (+5.8%)
|
2.60B
est: 2.60B (-0.1%)
|
3.07B
3.07B – 3.07B
+17.8% YoY
|
3.54B
3.54B – 3.54B
+15.4% YoY
|
| EBITDA |
339.83M
est: 129.54M (+162.3%)
|
435.49M
est: 180.59M (+141.1%)
|
529.66M
est: 302.97M (+74.8%)
|
683.41M
est: 392.91M (+73.9%)
|
782.07M
est: 460.18M (+69.9%)
|
117.12M
est: 553.70M (-78.8%)
|
121.28M
est: 361.42M (-66.4%)
|
446.79M
est: 443.27M (+0.8%)
|
872.86M
est: 571.81M (+52.6%)
|
673.47M
673.47M – 673.47M
+17.8% YoY
|
777.13M
777.13M – 777.13M
+15.4% YoY
|
| EBIT |
315.67M
est: 103.12M (+206.1%)
|
406.85M
est: 143.76M (+183.0%)
|
489.87M
est: 241.18M (+103.1%)
|
633.08M
est: 312.77M (+102.4%)
|
717.45M
est: 366.33M (+95.9%)
|
30.90M
est: 440.77M (-93.0%)
|
19.47M
est: 287.70M (-93.2%)
|
334.38M
est: 336.62M (-0.7%)
|
736.22M
est: 434.24M (+69.5%)
|
511.44M
511.44M – 511.44M
+17.8% YoY
|
590.16M
590.16M – 590.16M
+15.4% YoY
|
| Net Income |
295.56M
est: 257.23M (+14.9%)
|
371.45M
est: 402.44M (-7.7%)
|
465.49M
est: 481.27M (-3.3%)
|
605.68M
est: 601.59M (+0.7%)
|
673.31M
est: 680.42M (-1.0%)
|
92.56M
est: 726.05M (-87.3%)
|
58.96M
est: 182.55M (-67.7%)
|
356.80M
est: 321.22M (+11.1%)
|
599.63M
est: 528.59M (+13.4%)
|
618.05M
618.05M – 618.05M
+16.9% YoY
|
703.43M
703.43M – 703.43M
+13.8% YoY
|
| SGA |
106.48M
est: 227.07M (-53.1%)
|
163.42M
est: 316.56M (-48.4%)
|
455.04M
est: 531.08M (-14.3%)
|
565.30M
est: 688.73M (-17.9%)
|
746.94M
est: 806.66M (-7.4%)
|
788.18M
est: 970.58M (-18.8%)
|
690.50M
est: 633.53M (+9.0%)
|
769.03M
est: 773.44M (-0.6%)
|
470.18M
est: 997.73M (-52.9%)
|
1.18B
1.18B – 1.18B
+17.8% YoY
|
1.36B
1.36B – 1.36B
+15.4% YoY
|
| EPS |
0.80
est: 0.62 (+29.0%)
|
0.93
est: 0.97 (-4.1%)
|
1.16
est: 1.16 (+0.0%)
|
1.51
est: 1.45 (+4.1%)
|
1.68
est: 1.64 (+2.4%)
|
0.22
est: 1.75 (-87.4%)
|
0.14
est: 0.44 (-68.2%)
|
0.86
est: 0.79 (+8.9%)
|
1.47
est: 1.30 (+13.1%)
|
1.52
1.52 – 1.52
+16.9% YoY
|
1.73
1.73 – 1.73
+13.8% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-11 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-08 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-07 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-06 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-04-30 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-29 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-28 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-27 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-24 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-23 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-22 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-21 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-17 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-16 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | VanEck - China New Economy ETF CNEW.AX | 0.93% | 658.5K | 0.95% |
| 2 | State Street SPDR S&P Emerging Asia Pacific ETF GMF | 0.01% | 58.4K | 0.49% |
| 3 | State Street SPDR Portfolio Emerging Markets ETF SPEM | 0.01% | 2.00M | 0.07% |
| 4 | Invesco FTSE All-World UCITS ETF FWRA.SW | 0.00% | 78.0K | 0.15% |
| 5 | Invesco FTSE All-World UCITS ETF FTWG.L | 0.00% | 77.8K | 0.15% |
| 6 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 103.7K | 0.29% |
| 7 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 23.1K | 0.26% |
| 8 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 10.3K | 0.48% |
| 9 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 1.14M | 0.06% |
| 10 | Schwab Emerging Markets Equity ETF SCHE | 0.00% | 86.6K | 0.06% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Danhe Chen | Financial Director & Accounting Supervisor | — | female |
| Dong Yang Ruan | Administrative Director | — | male |
| Jiong Luo | GM & Director | — | male |
| Xiannan Hua | Board Secretary | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 002901.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
